PCSK9 is a critical regulator of the innate immune response and septic shock outcome-Reference-Cited by-同舟云学术

PCSK9 is a critical regulator of the innate immune response and septic shock outcome

Published:2014-10-15 Issue:258 Volume:6 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Walley Keith R.¹,Thain Katherine R.¹,Russell James A.¹,Reilly Muredach P.²,Meyer Nuala J.³⁴,Ferguson Jane F.²,Christie Jason D.³⁴⁵,Nakada Taka-aki⁶,Fjell Chris D.¹,Thair Simone A.¹,Cirstea Mihai S.¹,Boyd John H.¹

Affiliation:

1. Centre for Heart Lung Innovation, University of British Columbia, Vancouver V6Z 1Y6, Canada.

2. Cardiovascular Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.

3. Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.

4. Center for Translational Lung Biology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.

5. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.

6. Department of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, Chiba 260-8677, Japan.

Abstract

Inhibition of PCSK9 function is associated with an increase in pathogen lipid clearance, a decrease in the innate immune inflammatory response, and an improvement in septic shock clinical outcome.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference49 articles.

1. Distribution and Kinetics of Lipoprotein-Bound Lipoteichoic Acid

2. The Candida albicans Phospholipomannan Is a Family of Glycolipids Presenting Phosphoinositolmannosides with Long Linear Chains of β-1,2-Linked Mannose Residues

3. Crosstalk between reverse cholesterol transport and innate immunity

4. Mode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice.

5. Plasma PLTP (phospholipid-transfer protein): an emerging role in ‘reverse lipopolysaccharide transport’ and innate immunity

Cited by 300 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PCSK9 inhibition protects mice from food allergy;Translational Research;2024-10

2. Proprotein Convertase Subtilisin/Kexin Type 9 Induction in COVID-19 Is Poorly Associated with Disease Severity and Cholesterol Levels;Infectious Disease Reports;2024-07-17

3. Lessons From the LIPid Intensive Drug therapy for Sepsis Pilot (LIPIDS-P) Trial*;Critical Care Medicine;2024-07-15

4. Proprotein convertase subtilisin/kexin type 9 inhibitors protect against contrast-associated acute kidney injury in patients with atherosclerotic cardiovascular disease;Frontiers in Cardiovascular Medicine;2024-07-11

5. Assessment of serum proprotein convertase subtilisin/kexin type 9 in pediatric sepsis syndrome;Scientific Reports;2024-07-07